These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4066634)

  • 61. [Hepatitis C virus infection among the plasmapheresis donors].
    Wang S; Ding H; Zhang H
    Zhonghua Liu Xing Bing Xue Za Zhi; 1994 Apr; 15(2):71-3. PubMed ID: 7522967
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Levels of plasma proteins in blood donors in long-term plasmapheresis. I].
    Smálik S; Beranová G; Strzínek M
    Bratisl Lek Listy; 1971; 56(2):187-96. PubMed ID: 4109999
    [No Abstract]   [Full Text] [Related]  

  • 63. Sensitization of repeat plasmapheresis donors to ethylene oxide gas.
    Dolovich J; Sagona M; Pearson F; Buccholz D; Hiner E; Marshall C
    Transfusion; 1987; 27(1):90-3. PubMed ID: 3810833
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical plasmapheresis - who needs it?
    Gurland HJ; Dau PC; Lysaght MJ; Nose Y; Pusey CD; Siafaca K
    Trans Am Soc Artif Intern Organs; 1983; 29():774-81. PubMed ID: 6673324
    [No Abstract]   [Full Text] [Related]  

  • 65. [Epidemiological study of hepatitis C virus (HCV) infection in plasmapheresis and blood donors].
    Jin ZL; Chen SQ; Shi ZY
    Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Aug; 16(4):234-6. PubMed ID: 7585906
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Effects of plasmapheresis on the blood donors. Changes caused by long-term plasmapheresis in normal donors].
    Pistotnik M; Grgicević D; Flego DG
    Bilt Hematol Transfuz; 1975; 3(1-2):31-6. PubMed ID: 1225316
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA).
    Schulzki T; Seidel K; Storch H; Karges H; Kiessig S; Schneider S; Taborski U; Wolter K; Steppat D; Behm E; Zeisner M; Hellstern P;
    Vox Sang; 2006 Aug; 91(2):162-73. PubMed ID: 16907878
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Response to Volkow P et al. - Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities - International Journal of Drug Policy 20 (2009) 409-412.
    Penrod J; Gustafson M; Schreiber G; Bult J; Farrugia A
    Int J Drug Policy; 2010 Sep; 21(5):343-4; discussion 345-6. PubMed ID: 20547048
    [No Abstract]   [Full Text] [Related]  

  • 69. Markers of haemostatic activation before and after blood donation and plasmapheresis.
    Rahr HB; Roman C; Ingerslev J; Jørgensen J
    Vox Sang; 1997; 73(1):12-5. PubMed ID: 9269064
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bradykinin production during donor plasmapheresis procedures.
    Perseghin P; Capra M; Baldini V; Sciorelli G
    Vox Sang; 2001 Jul; 81(1):24-8. PubMed ID: 11520412
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Commitment in plasmapheresis donation: A study of determinants among regular donors in plasmapheresis].
    Delépine-Farvacques S; Terrade F; Danic B; Lebaudy JP
    Transfus Clin Biol; 2017 Jun; 24(2):38-46. PubMed ID: 28336244
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Blood investigation.
    AIDS Policy Law; 1996 May; 11(9):12. PubMed ID: 11363471
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers.
    Tran-Mi B; Storch H; Seidel K; Schulzki T; Haubelt H; Anders C; Nagel D; Siegler KE; Vogt A; Seiler D; Hellstern P
    Vox Sang; 2004 Apr; 86(3):189-97. PubMed ID: 15078254
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An improved modification of cycle filtration leucopheresis.
    Kretschmer V; Mueller-Eckhardt C
    Blut; 1977 Nov; 35(5):415-8. PubMed ID: 922171
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Repercussions of the staggering increase of medical care costs in the Blood Transfusion Services].
    Hassig A
    Rev Fr Transfus Immunohematol; 1977 Dec; 20(4):559-63. PubMed ID: 601398
    [No Abstract]   [Full Text] [Related]  

  • 76. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
    Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
    Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of plasmapheresis on the blood cells of RH(-) donors immunized with RH(+) blood.
    Raicheva D; Ivanova L; Dobreva A
    C R Acad Bulg Sci; 1976; 29(10):1547-50. PubMed ID: 828104
    [No Abstract]   [Full Text] [Related]  

  • 78. [Principles and methods of using apparatus for plasmocytapheresis with donors and patients].
    Kalinin NN
    Probl Gematol Pereliv Krovi; 1981 Jun; 26(6):11-6. PubMed ID: 7279882
    [No Abstract]   [Full Text] [Related]  

  • 79. Asking for something different from our donors: factors influencing persuasion success.
    Bagot KL; Bove LL; Masser BM; White KM
    Transfusion; 2014 Mar; 54(3 Pt 2):848-55. PubMed ID: 24274901
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [The effect of conversion from blood donation to plasma donation on serum ferritin and hemoglobin].
    Flesland O; Halvorsen R; Solheim BG; Orjasaeter H
    Tidsskr Nor Laegeforen; 1991 Jan; 111(2):189-90. PubMed ID: 1998176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.